[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F: Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer; 2004 May 10;109(6):926-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary.
  • We evaluated whether tracer FDG uptake, quantified as an SUV by PET in ovarian epithelial tumors, correlates with clinical stage, tumor grade, cell proliferation and glucose metabolism, all of which are biomarkers for response to chemotherapy, prognosis and overall survival in ovarian cancer patients.
  • Seventeen patients suspected of having ovarian cancer by physical examination, tumor marker analysis and anatomic imaging (such as sonography, CT and/or MRI) underwent whole-body FDG-PET within the 2 weeks prior to surgery.
  • Seventeen epithelial ovarian tumor specimens (13 malignant tumors, 5 at stage I, 2 at stage II, 6 at stage III; 2 borderline tumors; and 2 benign lesions) were available for pathologic evaluation.
  • Therefore, glucose consumption, as determined by analysis of SUVs in FDG-PET, may be a noninvasive biomarker for ovarian epithelial tumors.
  • [MeSH-major] Fluorodeoxyglucose F18 / pharmacokinetics. Ki-67 Antigen / metabolism. Monosaccharide Transport Proteins / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radionuclide imaging. Biomarkers, Tumor. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / radionuclide imaging. Cell Division. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radionuclide imaging. Female. Glucose / metabolism. Glucose Transporter Type 1. Humans. Neoplasm Staging. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15027127.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Ki-67 Antigen; 0 / Monosaccharide Transport Proteins; 0 / Radiopharmaceuticals; 0 / SLC2A1 protein, human; 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose
  •  go-up   go-down


2. Bing Z, Adegboyega PA: Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors. Appl Immunohistochem Mol Morphol; 2005 Mar;13(1):104-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors.
  • The authors report the first case of ovarian mucinous adenocarcinoma with metastasis from a synchronous small cell neuroendocrine carcinoma of the lung.
  • The patient received 3 cycles of chemotherapy with carboplatin and subsequently underwent a supracervical hysterectomy and bilateral salpingo-oophorectomy.
  • A large, multiloculated cystic mass was found arising from the right ovary.
  • Microscopic examination disclosed a mucinous neoplasm with both mucinous cystadenoma and mucinous papillary adenocarcinoma components.
  • A microscopic focus of cells with "atypical" cytomorphologic features was detected within the mucinous neoplasm.

  • Genetic Alliance. consumer health - Ovarian small cell carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15722802.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 1.11.1.- / Peroxidases
  •  go-up   go-down


3. Yokoyama Y, Kaji H, Kondoh H, Takeuchi E, Yamasaki Y, Inui Y: Complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin. Gynecol Obstet Invest; 2001;52(3):210-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin.
  • BACKGROUND: The survival rate of patients with advanced-stage mucinous cystadenocarcinoma of the ovary is dismal and no best treatment is known.
  • We report a case of complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin.
  • CASE: A 51-year-old nullipara diagnosed with International Federation of Gynecology and Obstetrics stage IV mucinous cystadenocarcinoma of the ovary underwent cytoreductive surgery followed by systemic chemotherapy employing paclitaxel and carboplatin every 4 weeks for 3 courses.
  • The patient tolerated chemotherapy well, demonstrated a remarkable response showing no evidence of malignancy at a second-look laparotomy.
  • As a consolidation chemotherapy after negative second-look laparotomy, she underwent another three courses of chemotherapy of the same regimen, and is showing no evidence of disease.
  • CONCLUSION: Paclitaxel and carboplatin may be effective in treating mucinous cystadenocarcinoma of the ovary.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Mucinous / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11598367.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. Zhang J, Chen AP, Wang B, Zhao SP, Liu LZ, Dai SZ: [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer]. Ai Zheng; 2008 Dec;27(12):1331-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer].
  • BACKGROUND & OBJECTIVE: Abnormal expression and activation of epidermal growth factor receptor (EGFR), which is closely related to the recurrence and poor prognosis of ovarian cancer, can promote chemotherapy resistance of tumor cells.
  • Lung resistance protein (LRP), a multidrug resistance protein causing platinum-resistance, is an independent factor in predicting chemotherapy sensitivity to ovarian cancer.
  • This study was to explore the correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer.
  • METHODS: Expressions of EGFR and LRP in 76 specimens of ovarian malignant tumor, nine borderline tumor, 17 benign tumor and 15 normal ovary were studied using immunohistochemistry.
  • Patients with ovarian cancer were followed up.
  • Correlations of EGFR and LRP to chemotherapy efficacy and survival time of patients with ovarian cancer after operation were analyzed.
  • EGFR was highly expressed in ovarian cancer patients at late stage (III-IV), with poor differentiation and ascites (P <0.05).
  • The short-term efficacy rates of ovarian cancer were lower in patients with positive expressions of EGFR and LRP (57.14% and 53.70%) than in those with negative expressions (P<0.05).
  • The positive rates of EGFR and LRP were significant higher in patients with chemotherapy resistance (92.86% and 85.71%) than in those sensitive to chemotherapy (P<0.05).
  • The three-year survival rate of ovarian cancer patients was 53.00%.
  • Patients with positive EGFR and LRP and poor short-term efficacy after chemotherapy had short survival time (P<0.01).
  • CONCLUSION: The expression of EGFR and LRP could be used to predict chemotherapy resistance and prognosis of ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Drug Resistance, Neoplasm. Ovarian Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cisplatin / pharmacology. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Mucinous / drug therapy. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080004.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Chang WC, Sheu BC, Lin MC, Chow SN, Huang SC: Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report. Int J Gynecol Cancer; 2005 May-Jun;15(3):549-53
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report.
  • Epithelial ovarian tumors of borderline malignancy are tumors with histologic features and biologic behavior between benign and frankly malignant epithelial ovarian neoplasms.
  • Here, we present a 35-year-old patient with carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian tumor of borderline malignancy.
  • Total hysterectomy, bilateral salpingo-oophorectomy, appendectomy, and omentectomy were performed, and the frozen pathology during operation showed mucinous tumor of borderline malignancy of left ovary on April 18, 2002.
  • The patient was followed at our outpatient department for 19 months after operation and was free of the disease without any adjuvant chemotherapy.
  • It is difficult to determine whether intestinal-type borderline mucinous tumors with intraepithelial carcinoma are associated with a worse prognosis compared with those with epithelial atypia alone due to disparate results in the published literature.
  • However, too few cases of carcinosarcoma-like mural nodule in mucinous tumor have been published to warrant a conclusion regarding their prognosis.
  • [MeSH-major] Carcinosarcoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882184.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer; 2009 Jul;19(5):860-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
  • To evaluate the potential of epithelial cell adhesion molecule (Ep-CAM/TROP-1)-specific immunotherapy against epithelial ovarian carcinomas (EOCs), we have analyzed the expression of Ep-CAM at RNA and protein level in patients harboring primary, metastatic, and chemotherapy-resistant/recurrent EOC.
  • Epithelial cell adhesion molecule expression was evaluated by real-time polymerase chain reaction and immunohistochemistry in 168 fresh-frozen biopsies and paraffin-embedded tissues.
  • In addition, Ep-CAM surface expression was evaluated by flow cytometry in several freshly established ovarian carcinoma cell lines derived from patients harboring tumors resistant to chemotherapy in vivo as well as in vitro.
  • Epithelial cell adhesion molecule transcript was found significantly overexpressed in primary, metastatic, and recurrent EOC when compared with normal human ovarian surface epithelium cell lines and fresh-frozen normal ovarian tissue (P < 0.001).
  • Similarly, by immunohistochemistry, Ep-CAM protein expression was found significantly higher in primary, metastatic, and recurrent EOC when compared with normal ovarian tissues.
  • Of interest, metastatic/recurrent tumors were found to express significantly higher levels of Ep-CAM protein when compared with primary ovarian carcinomas (P < 0.001).
  • Finally, a high surface expression of Ep-CAM was found in 100% (5/5) of the chemotherapy-resistant ovarian carcinoma cell lines studied by flow cytometry.
  • These results demonstrate high Ep-CAM overexpression in ovarian carcinoma, especially in metastatic and recurrent/chemotherapy-resistant ovarian disease.
  • The lack of Ep-CAM expression on the chelomic epithelium in the peritoneal cavity, combined with the recent development of fully human monoclonal antibodies against this surface molecule, suggest Ep-CAM as a promising target for antibody-mediated therapies in ovarian carcinoma patients harboring tumors refractory to standard treatment modalities.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Adhesion Molecules / metabolism. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Blotting, Western. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / secondary. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / secondary. Female. Flow Cytometry. Humans. Immunoenzyme Techniques. Middle Aged. Organoplatinum Compounds / administration & dosage. Ovary / metabolism. Ovary / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574774.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Organoplatinum Compounds; 0 / RNA, Messenger
  •  go-up   go-down


7. Salomon LJ, Lhommé C, Pautier P, Duvillard P, Morice P: Safety of simple cystectomy in patients with unilateral mucinous borderline tumors. Fertil Steril; 2006 May;85(5):1510.e1-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of simple cystectomy in patients with unilateral mucinous borderline tumors.
  • OBJECTIVE: To report on ovarian carcinoma development after cystectomy for a borderline mucinous ovarian tumor.
  • PATIENT(S): One patient who developed recurrence in the form of an invasive ovarian carcinoma after simple cystectomy for a borderline mucinous ovarian tumor.
  • Histological examination revealed a borderline mucinous ovarian tumor.
  • No additional treatment was prescribed.
  • Two years later, the patient relapsed with a malignant mucinous ovarian carcinoma.
  • She underwent surgical resection and staging, including hysterectomy, bilateral adnexectomy, omentectomy, and pelvic and para-aortic lymphadenectomy, and platinum-based chemotherapy.
  • CONCLUSION(S): Recurrence in the form of invasive ovarian carcinoma may occur in the same ovary after cystectomy in cases of borderline mucinous ovarian tumor.
  • Such treatment enables preservation of reproductive potential and reduces the risk of developing invasive carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Cystectomy / adverse effects. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / prevention & control. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647380.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Everett EN, French AE, Stone RL, Pastore LM, Jazaeri AA, Andersen WA, Taylor PT Jr: Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol; 2006 Aug;195(2):568-74; discussion 574-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer.
  • OBJECTIVE: The purpose of this study was to evaluate differences in morbidity, progression-free interval, and survival in women with advanced epithelial ovarian cancer treated with initial chemotherapy versus initial surgery.
  • STUDY DESIGN: All women with epithelial ovarian cancer who were treated surgically at our hospital between January 1, 1995, and January 1, 2003, were eligible; the cases of 200 patients met the criteria and underwent retrospective chart review.
  • RESULTS: Ninety-eight patients (49%) had initial chemotherapy, and 102 patients (51%) had initial surgery.
  • Patients who received initial chemotherapy were more likely to have stage IV disease (initial chemotherapy, 27%, vs initial surgery, 8%; P = .042) and grade 3 disease (initial chemotherapy, 73%, vs initial surgery, 61%; P = .025).
  • Optimal cytoreduction was achieved more often in patients who received initial chemotherapy (initial chemotherapy, 86%, vs initial surgery, 54%; P < .001).
  • Only optimal cytoreduction (P = .022), and not treatment choice (P = .089), had an impact on median survival.
  • CONCLUSION: Initial chemotherapy is a reasonable alternative to initial surgery for the treatment of selected patients with advanced epithelial ovarian cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cystadenocarcinoma / drug therapy. Cystadenocarcinoma / surgery. Cystadenocarcinoma, Serous / drug therapy. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Comorbidity. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / surgery. Disease Progression. Female. Humans. Middle Aged. Morbidity. Neoplasm Staging. Ovary / surgery. Retrospective Studies. Survival Analysis


9. Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T, Kaku T: Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol; 2009 Jun;113(3):331-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
  • OBJECTIVE: We conducted the present study to clarify the clinicopathological characteristics of mucinous adenocarcinoma.
  • METHODS: Two hundred twenty-five patients were diagnosed with mucinous adenocarcinoma at individual institutes and underwent primary treatment between 1998 and 2003.
  • Of 189 patients undergoing central pathological review, 64 patients (33.9%) were diagnosed with mucinous invasive adenocarcinoma, 45 mucinous intraepithelial carcinoma, and 42 mucinous tumor of borderline malignancy.
  • Twenty-five patients were diagnosed with other histological subtypes, including 8 endometrioid adenocarcinoma, 5 clear cell carcinoma, 3 serous adenocarcinoma, and 4 mixed type.
  • There were 13 cases of metastatic mucinous adenocarcinoma, including 7 pseudomyxoma peritonei.
  • RESULTS: Forty-five patients with mucinous invasive carcinoma were in FIGO I-II stages and 19 in III-IV stages.
  • There was no difference in the outcome between mucinous invasive adenocarcinoma and serous adenocarcinoma in I-II stage patients and III-IV stage patients with optimal operation.
  • In contrast, patients with mucinous invasive adenocarcinoma receiving suboptimal operation showed a significantly worse prognosis (survival rate: 27.8% vs. 61.5%).
  • The response rate to chemotherapy for mucinous invasive adenocarcinoma was significantly lower than for serous adenocarcinoma (12.5% vs. 67.7%).
  • CONCLUSIONS: The diagnosis of mucinous invasive adenocarcinoma was difficult.
  • Since patients with mucinous invasive adenocarcinoma had a lower response to chemotherapy, aggressive cytoreductive surgery was an effective treatment to improve the prognosis for advanced stage patients.
  • A new chemotherapeutic regimen should be established for mucinous adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Case-Control Studies. Female. Humans. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275957.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Sato S, Kobayashi Y, Okuma Y, Kondo H, Kanishi Y, Saito K, Kiguchi K: Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary. Hum Cell; 2002 Sep;15(3):171-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary.
  • We recently established a cell line (designated 371M) derived from an ovarian mucinous cystadenocarcinoma.
  • The tumor cells were obtained from the ascitic fluid of a 54-year-old Japanese woman while she was undergoing surgery.
  • Adjuvant chemotherapy (combined paclitaxel and carboplatin) was administered, but was ineffective, and she died about 4 months after surgery.
  • They proliferated in a monolayered sheet with doubling times of 84 h and 37 h in the 10th and 34th passages, respectively.
  • When transplanted into nude mice, the tumor histopathologically resembled the structure of the original tumor.
  • Sensitivity of 371M cells to a variety of anti-cancer drugs was examined by in vitro MTT assay, and the results suggested that CPT-11 and CDDP were more effective against 371M cells than other anti-cancer agents.
  • [MeSH-major] Camptothecin / analogs & derivatives. Cell Culture Techniques / methods. Cystadenocarcinoma, Mucinous. Ovarian Neoplasms
  • [MeSH-minor] Animals. Antigens, Tumor-Associated, Carbohydrate. Antineoplastic Agents / pharmacology. Biomarkers, Tumor. Cell Division. Cisplatin / pharmacology. Drug Screening Assays, Antitumor. Female. Humans. Karyotyping. Mice. Mice, Nude. Middle Aged. Neoplasm Transplantation. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rep. 1987 Dec;71(12):1231-7 [3319135.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1985 Sep;37(9):1820-4 [4056530.001]
  • [Cites] Hum Cell. 1990 Mar;3(1):52-6 [2083224.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(4):278-82 [11695809.001]
  • [Cites] Cancer Res. 1989 Sep 15;49(18):5153-61 [2548714.001]
  • [Cites] Hum Cell. 1995 Dec;8(4):189-94 [8721090.001]
  • [Cites] Gynecol Oncol. 1991 Feb;40(2):118-28 [2010102.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Nov;18(11):1069-74 [6891650.001]
  • [Cites] Hum Cell. 1997 Sep;10(3):199-208 [9436040.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3103-8 [8319218.001]
  • [Cites] Hum Cell. 1999 Dec;12(4):211-7 [10834108.001]
  • [Cites] Cancer Res. 1985 Feb;45(2):826-32 [2981614.001]
  • [Cites] Jpn J Cancer Res. 1994 Dec;85(12):1247-56 [7852189.001]
  • [Cites] Cancer Chemother Rep. 1974 Mar-Apr;58(2):271-3 [4830501.001]
  • (PMID = 12703547.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0H43101T0J / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


11. Swiatkowska-Freund M, Preis K, Emerich J: [Appendiceal mucinous carcinoma]. Ginekol Pol; 2000 Oct;71(10):1277-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Appendiceal mucinous carcinoma].
  • Preoperative diagnosis of this kind of neoplasm is difficult.
  • We present a case of a woman admitted to the hospital with diagnosis of adnexal tumor of the right ovary.
  • Laparotomy was performed and tumor of appendix was found.
  • There was also a small tumor (2 cm) in small bowel and some increased lymphatic nodules.
  • Uterus with adnexis, tumor of appendix, part of small bowel and colon were resected.
  • Because of infiltration of the neoplasm a part of the bladder was resected as well.
  • She received chemotherapy with 5-FU.
  • After 9 months computed tomography revealed no changes in abdomen.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Appendiceal Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Humans. Intestinal Neoplasms / secondary. Intestinal Neoplasms / therapy. Laparotomy. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11143937.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Shimada K, Iwase K, Aono T, Takeda S, Yoshida H, Koma M, Nomura M, Nishikawa K, Tamagawa H, Matsuda C, Fushimi H, Tanaka Y: A case of advanced mucinous cystadenocarcinoma of the pancreas with peritoneal dissemination responding to gemcitabine. Gan To Kagaku Ryoho; 2009 Jun;36(6):995-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of advanced mucinous cystadenocarcinoma of the pancreas with peritoneal dissemination responding to gemcitabine.
  • Mucinous cystic neoplasm(MCN)of the pancreas is a rare disease.
  • A 34-year-old female was referred to our hospital for a giant cystic tumor in the left epigastrium, suspected of being a pancreatic MCN.
  • The surgical findings revealed that the tumor originated in the pancreatic tail with the presence of peritoneal dissemination.
  • A distal pancreatectomy and a splenectomy were performed, and the resected specimen histologically revealed an invasive mucinous cystadenocarcinoma of the pancreas.
  • The postoperative computed tomography(CT)scan showed metastatic tumors of the Douglas pouch and the left ovary.
  • Gemcitabine(GEM)was thereafter systemically administered for palliative chemotherapy with a regimen of 1,000 mg/m / 2week for 3 weeks, followed by a week of rest.
  • When assessed by a CT scan after 4 courses of chemotherapy, marked shrinkage of the tumors was identified, and we could not detect the tumors clearly.
  • Therefore, systemic chemotherapy with GEM is considered to possibly be an effective treatment against MCN.
  • We describe herein the first case of advanced mucinous cystadenocarcinoma of the pancreas with peritoneal dissemination responding to GEM and a brief review of the literature.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / pathology. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Peritoneum / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Female. Humans. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542723.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


13. Kikkawa F, Nawa A, Kajiyama H, Shibata K, Ino K, Nomura S: Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol Oncol; 2006 Oct;103(1):171-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and prognosis of mucinous tumors of the ovary.
  • OBJECTIVE: Ovarian mucinous tumors consist of benign, borderline, and carcinomatous tumor, but the clinical characteristics of these 3 types have not been investigated in detail.
  • In this study, we compared the clinical characteristics and prognosis among these 3 types of mucinous tumors.
  • METHODS: One hundred sixty-one patients with mucinous cystadenocarcinoma and 143 patients with mucinous borderline tumor were registered between 1986 and 2003.
  • All patients were reviewed by two pathologists, then the mixed type and cases showing other organized malignant tumors were excluded from this study.
  • Patients with mucinous carcinoma staged Ib or more were treated postoperatively with 6 cycles of platinum-based chemotherapy.
  • RESULTS: Mean patient ages were 43.9, 44.7, and 49.7 years in patients with benign, borderline, carcinomatous tumor, respectively.
  • The ratio of early stage (I, II) to advanced stage (III, IV) was significantly lower in carcinoma than in borderline tumor.
  • The levels of tumor markers tended to increase with the level of malignancy.
  • In borderline tumor, 5 patients died of disease, and all of these patients had stage III disease with residual tumor after the initial surgery.
  • Patients with borderline tumor showed significantly better prognosis than those with carcinoma; however, there were no significant differences in prognosis between borderline tumor and carcinoma in patients with stage III tumor or residual tumor.
  • CONCLUSIONS: In mucinous tumors, measurement of CA72-4 is recommended to distinguish malignant from benign tumors.
  • Even in borderline tumor, patients with residual tumor showed a poorer prognosis than carcinoma, suggesting that complete resection is necessary for a good prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546243.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Papathanasiou K, Tolikas A, Dovas D, Kostopoulou E, Fragkedakis N, Tzafettas J: Simultaneously detected primary malignant tumors of ovary and endometrium with unusual histology. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1191-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneously detected primary malignant tumors of ovary and endometrium with unusual histology.
  • A case of a mucinous adenocarcinoma of the ovary with a synchronous endometroid tumor of the endometrium with focal features of undifferentiated carcinoma and deep myometrial invasion is reported.
  • A review of the literature revealed that our case is interesting in view of the fact that simultaneous presentation of primary ovarian and endometrial neoplasms is rare and usually related to low-stage ovarian lesions and well-differentiated and superficial endometrial carcinomas in contrast to our case with the focal features of undifferentiated carcinoma and the deep myometrial invasion.
  • The prognosis in most of the cases is surprisingly good even after total abdominal hysterectomy and bilateral oophorectomy alone without adjuvant chemotherapy or irradiation.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343211.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N: Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol; 2002 Aug;100(2):281-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.
  • All patients underwent cytoreductive surgery followed by platinum-based chemotherapy.
  • Response rate to chemotherapy was 14.6% for clear cell carcinoma and 72.2% for serous adenocarcinoma.
  • The expression of P-glycoprotein and multidrug resistance-associated protein did not differ between responders and nonresponders in both tumor types.
  • The LI for responders was significantly higher than that for nonresponders in both tumor types.
  • Multivariable analysis revealed that LI and residual tumor size were the independent prognostic factors.
  • CONCLUSION: Lower proliferation of tumor may be a behavior of clear cell carcinoma of the ovary that contributes to its resistance to chemotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Drug Resistance, Multiple. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Division / drug effects. Cell Division / physiology. Chemotherapy, Adjuvant. Cohort Studies. Confidence Intervals. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Multivariate Analysis. Neoplasm Staging. Ovariectomy / methods. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12151151.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


16. Mecke H, Börner-Klaussner B, Grosse G, Nadjari B, Hauptmann S: [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy]. Zentralbl Gynakol; 2000;122(5):274-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
  • [Transliterated title] Zum klinischen Verhalten von serösen und muzinösen Borderline-Tumoren des Ovars mit diploider DNA-Stammlinie. Verlaufsbeobachtungen nach organerhaltender und nicht-organerhaltender Therapie.
  • Even today, the situation is still unclear with regard to the radicality of the operation and any adjuvant therapy required in treatment of borderline tumors of the ovary.
  • In the last two decades, treatment of these tumors in the Department of Gynecology and Obstetrics at our hospital has depended on the stage of the disease and the age of the patient.
  • Histologically, 14 borderline tumors were mucinous, 21 were serous.
  • In this period, no patient died of borderline tumor.
  • Only one patient received adjuvant chemotherapy.
  • Later, these could no longer be demonstrated (one patient) or did not affect the survival time (three patients) and thus ultimately was not pathologically relevant.
  • It is not possible to make a definitive treatment recommendation on the basis of this investigation because the number of patients followed up was too small.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / surgery. Cystadenocarcinoma, Serous / surgery. DNA, Neoplasm / genetics. Diploidy. Hysterectomy. Ovarian Neoplasms / surgery. Ovariectomy. Precancerous Conditions / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Flow Cytometry. Follow-Up Studies. Humans. Laparoscopy. Middle Aged. Neoplasm Staging. Ovary / pathology. Prognosis. Reoperation

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10857214.001).
  • [ISSN] 0044-4197
  • [Journal-full-title] Zentralblatt für Gynäkologie
  • [ISO-abbreviation] Zentralbl Gynakol
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


17. Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG, Janssen EA, Baak JP, Rollason TP: The prognostic and predictive value of syntactic structure analysis in serous carcinoma of the ovary. Int J Gynecol Pathol; 2008 Apr;27(2):191-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic and predictive value of syntactic structure analysis in serous carcinoma of the ovary.
  • The objective of this study was to determine whether syntactic structure analysis (SSA) can predict survival outcome and chemotherapeutic response in ovarian carcinoma.
  • Syntactic structure analysis parameters, blindly determined in archived hematoxylin and eosin sections of 132, International Federation of Gynecology and Obstetrics (FIGO) stage I to IV serous ovarian tumors, and clinicopathologic parameters were evaluated as to their univariate and multivariate prognostic value and ability to predict chemotherapy response as measured by changes in CA125 levels.
  • Univariate analysis revealed FIGO stage, tumor grade, preoperative CA125, presence of ascites, extent of disease residuum, and the SSA parameters minimum spanning tree (min MST), maximum MST (max MST), percent connectivity to 1, and 2 nearest neighbors to be significant predictors of overall survival and disease-free survival.
  • Tumor grade, FIGO stage, extent of disease residuum, presence of ascites, and percent connectivity to 2 nearest neighbors were found to be significant predictors of chemotherapy response.
  • Multivariate analysis revealed extent of disease residuum to be a significant predictor for overall survival (P <or= 0.01) and prediction of chemotherapy response (P = 0.05).
  • Syntactic structure analysis features can predict survival outcome and chemotherapy response in ovarian carcinoma but, with multivariate analysis, are overshadowed by FIGO stage and residual disease.
  • [MeSH-major] Models, Theoretical. Neoplasms, Cystic, Mucinous, and Serous / diagnosis. Neoplasms, Cystic, Mucinous, and Serous / pathology. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Staging. Observer Variation. Predictive Value of Tests. Prognosis. Reproducibility of Results. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317224.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Shimoyama S, Kuramoto S, Kawahara M, Yamasaki K, Endo H, Murakami T, Kaminishi M: A rare case of pseudomyxoma peritonei presenting an unusual inguinal hernia and splenic metastasis. J Gastroenterol Hepatol; 2001 Jul;16(7):825-9
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is a case report of a PMP patient who had splenic metastasis and showed an inguinal tumor as an initial presentation.
  • A 59-year-old female patient, who had undergone bilateral oophorectomy because of a ruptured ovarian mucinous tumor of boderline malignancy 12 years previously, presented a presumptive diagnosis of a left inguinal irreducible hernia.
  • Computed tomography revealed a low density mass in the pelvic cavity and in the inguinal lesion, as well as in the spleen without any diseases around the organ.
  • The patient underwent a resection of gelatinous tumor in the pelvic cavity, splenectomy, and appendectomy, as well as left inguinal herniorrhaphy.
  • Histological examinations revealed a splenic metastasis of PMP originating from the ovarian low-grade mucinous tumor.
  • She received postoperative intraperitoneal lavage as well as chemotherapy, and has survived for over 7 years postoperatively without any evidence of recurrence, as confirmed by repeated follow-up CT examinations and CEA determination.
  • Furthermore, it should be noted that an inguinal tumor can sometimes be an initial presentation of PMP.
  • [MeSH-minor] Carcinoembryonic Antigen / blood. Cystadenoma, Mucinous / pathology. Female. Humans. Middle Aged. Ovarian Neoplasms / pathology. Ovariectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11446896.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


19. Costa MJ, Hansen CL, Holden JA, Guinee D Jr: Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum. Int J Gynecol Pathol; 2000 Jul;19(3):248-57
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum.
  • We test the hypothesis that the percentage of TopoIIa immunoreactive nuclei (TopoIIaI) aids in the treatment and prognostic evaluation of ovarian and primary peritoneal surface epithelial neoplasms (SENs) and correlates with established cell cycle control markers: p53, p21WAF1/CIP1 (p21), and Ki67.
  • TopoIIaI correlated with SEN architectural/nuclear grade (p < 10(-5)/10(-7)), but not histologic type.
  • The patients in this retrospective series of SEN were treated primarily with platinum-based chemotherapy.
  • These data may suggest further prospective studies in which patients with SENs exhibiting high TopoIIaI are treated with chemotherapy targeted against TopoIIa (e.g., etoposide).
  • In this retrospective series, high SEN TopoIIaI predicted poor survival when treated with platinum-based chemotherapy, which does not target TopoIIa.
  • [MeSH-major] Biomarkers / analysis. Cell Cycle. DNA Topoisomerases, Type II / analysis. Ovarian Neoplasms / enzymology. Peritoneal Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Mucinous / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Cell Nucleus / enzymology. Cell Nucleus / pathology. Cystadenocarcinoma, Serous / enzymology. Cystadenocarcinoma, Serous / pathology. Endometrium / pathology. Female. Humans. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Metastasis. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10907174.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


20. Tropé CG, Kristensen G, Makar A: Surgery for borderline tumor of the ovary. Semin Surg Oncol; 2000 Jul-Aug;19(1):69-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for borderline tumor of the ovary.
  • A more correct staging procedure, classification of true serous implants, and agreement on how the presence of gelatinous ascites in mucinous tumors contributes to cancer stage might change the distribution of stage and survival data by stage for women with borderline tumors in the future.
  • Independent prognostic factors for patients with borderline tumors without residual tumor after primary surgery are: DNA ploidy, morphometry, International Federation of Gynecology and Obstetrics (FIGO) stage, histologic type, and age.
  • Different types of surgery and chemotherapy were not independent prognostic factors.
  • 3) Do patients with borderline tumors benefit from adjuvant treatment?
  • [MeSH-major] Carcinoma / pathology. Carcinoma / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Incidence. Neoplasm Staging. Reoperation. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10883027.001).
  • [ISSN] 8756-0437
  • [Journal-full-title] Seminars in surgical oncology
  • [ISO-abbreviation] Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 49
  •  go-up   go-down


21. Camatte S, Morice P, Atallah D, Pautier P, Lhommé C, Haie-Meder C, Duvillard P, Castaigne D: Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies. J Am Coll Surg; 2002 Sep;195(3):332-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies.
  • BACKGROUND: The aim of this study is to evaluate the rate and the clinical outcomes of lymph node involvement in patients treated for borderline ovarian tumor (BOT).
  • STUDY DESIGN: Forty-two patients were treated for BOT with a procedure that included lymphadenectomy.
  • Thirty-two patients underwent systematic lymphadenectomy, five because of associated cancer (uterine cervix or corpus) and five because of bulky nodes discovered during the surgical procedure.
  • None of the patients with a mucinous tumor had nodal involvement.
  • None of the patients with nodal involvement died of borderline tumor.
  • One patient died of a complication of adjuvant therapy (leukemia after chemotherapy).
  • CONCLUSIONS: The prognosis of patients with borderline tumors of the ovary and nodal involvement is excellent.
  • This procedure should be carried out in patients with serous tumor and enlarged lymph nodes.
  • [MeSH-major] Lymphatic Metastasis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Combined Modality Therapy. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / therapy. Cystadenoma, Serous / pathology. Cystadenoma, Serous / therapy. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Neoplasms, Complex and Mixed / pathology. Neoplasms, Complex and Mixed / therapy. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12229940.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W: The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Oncol Res; 2010;18(7):343-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms.
  • The role of estrogens in ovarian carcinogenesis and progression of ovarian cancer is unclear.
  • Cytochrome P450 is involved in estrogen metabolism, and polymorphisms have been associated with functional changes and risk for ovarian cancer.
  • In this study, we investigated the impact of the CYP1A1 Ile462Val polymorphism upon tumor risk and disease progression in ovarian cancer patients.
  • One hundred and eleven ovarian cancer patients who had been treated at the University Hospital of Essen between 1999 and 2007 and 119 age-matched healthy female controls were enrolled in this study.
  • The distribution of genotypes was statistically significant different between ovarian cancer patients and healthy controls.
  • We observed a significant association of the Ile allele with ovarian cancer (OR 2.6, 95% CI 1.5-4.7, p = 0.001).
  • We observed a statistically significant association between the 462Val allele and platinum resistance, which was defined as a time interval < 6 months to disease progression after administration of a platinum-based primary chemotherapy (OR 5.9, 95% CI 1.5-23.2, p = 0.005).
  • We observed a significant association between the presence of the 462Ile allele with ovarian cancer.
  • While there is uncertainty about the potential involvement of CYP1A1 in the metabolism of platinum-containing agents, our findings suggest an association between the 462Val allele and the development of platinum resistance in ovarian tumors.
  • If confirmed in a larger, independent collective, our findings would have important relevance with respect to the clinical consequences for the primary chemotherapy of ovarian cancer patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytochrome P-450 CYP1A1 / genetics. Drug Resistance, Neoplasm / genetics. Organoplatinum Compounds / therapeutic use. Ovarian Neoplasms / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Female. Genotype. Humans. Middle Aged. Ovary / metabolism. Ovary / pathology. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377136.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  •  go-up   go-down


23. Buttarelli M, Houvenaeghel G, Lelièvre L, Jacquemier J, Guiramand J, Delpero JR: [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?]. Ann Chir; 2006 Oct;131(8):431-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?].
  • [Transliterated title] Une exentération pelvienne postérieure avec anastomose est-elle faisable et justifiée dans le traitement des cancers de l'ovaire à un stade évolué?
  • PURPOSE: The aim of this study is to show that the removal of the rectum is not an obstacle to implement an optimal surgery in advanced epithelial cancer of the ovary.
  • MATERIAL AND METHODS: Retrospective study on a population of 44 women with advanced epithelial cancer of the ovary.
  • This treatment was completed by chemotherapy for 36 of them.
  • The completion of chemotherapy started after an average of 5.2 weeks after surgery.
  • CONCLUSION: The posterior exenteration, when it's necessary, for advanced epithelial cancer of the ovary must not be an obstacle to obtain an optimal surgery.
  • This surgical act is safe for the management of this pathology without delaying the others therapeutics and allowing a satisfactory quality of life.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Endometrioid / surgery. Carcinosarcoma / surgery. Colon / surgery. Ovarian Neoplasms / surgery. Pelvic Exenteration. Rectum / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Colostomy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Cystectomy. Feasibility Studies. Female. Humans. Hysterectomy. Ileostomy. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Ovary / pathology. Preoperative Care. Quality of Life. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707093.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Le T, Adolph A, Krepart GV, Lotocki R, Heywood MS: The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol; 2002 May;85(2):351-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
  • OBJECTIVE: The management of understaged patients with apparent clinically early ovarian cancer is difficult.
  • Options include offering chemotherapy based on histopathologic factors or reoperation to obtain the necessary information needed to assign an accurate surgical stage.
  • Patients not having surgical staging procedures were offered platinum-based chemotherapy based on high tumor grades, dense adhesions, and presence of surface excrescences or large necrotic areas.
  • Patients with surgically proven stage I disease were treated with no further therapy regardless of histopathologic factors.
  • RESULTS: One hundred and thirty-eight patients presented with tumor macroscopically confined to the ovary at the time of laparotomy.
  • The histology distribution was serous tumor in 28.3%, mucinous in 26.1%, endometrioid in 23.2%, clear cell in 14.5%, anaplastic in 2.2%, and mixed types in 5.8%.
  • Sixty-eight percent of the patients had a comprehensive surgical staging procedure initially.
  • Thirty-six percent of these patients were found to have extraovarian metastases and were subsequently treated with adjuvant chemotherapy.
  • Forty-three percent of those not having staging laparotomy were offered chemotherapy based on high risk factors only.
  • In terms of progression-free interval, only age (OR 1.027, P = 0.048) and tumor grade (OR 3.62, P = 0.05) are significant predictors.
  • CONCLUSION: Absence of surgical pathologic high-risk factors is inferior to comprehensive staging laparotomy findings in guiding recommendations for subsequent adjuvant therapy.
  • Patients who have not been properly staged stand a significant risk of recurrent disease despite more frequent use of chemotherapy.
  • All clinically early-stage ovarian cancer patients should be considered for comprehensive staging surgery prior to further treatment recommendations.
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Female. Humans. Laparotomy. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2002 Elsevier Science (USA).
  • (PMID = 11972399.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Ferrandina G, Stoler A, Fagotti A, Fanfani F, Sacco R, De Pasqua A, Mancuso S, Scambia G: p21WAF1/CIP1 protein expression in primary ovarian cancer. Int J Oncol; 2000 Dec;17(6):1231-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p21WAF1/CIP1 protein expression in primary ovarian cancer.
  • p21WAF1/CIP1 protein is a cyclin-dependent kinase inhibitor, able to prevent the CDK2/cyclin E induced retinoblastoma protein (pRB) phosphorylation, thus inhibiting cell cycle progression at G1 phase. p21WAF1/CIP1 protein levels were examined in a series of 102 ovarian tissue samples including normal ovary, primary ovarian tumors, omental metastasis, recurrent disease and residual tumor after chemotherapy exposure, by Western blot analysis.
  • The association of p21WAF1/CIP1 status with clinicopathological parameters and clinical outcome was also investigated. p21WAF1/CIP1 protein was detectable in 76 out of 102 (74%) ovarian tissue samples.
  • We observed a significant trend of p21 levels to gradually increase from normal ovarian tissues (median 0 a.u.) through primary ovarian cancers (median 0.19 a.u.
  • In the group of stage III-IV ovarian cancer patients, p21-positive cases showed a more favourable prognosis with respect to p21-negative cases: the 3-year time to progression (TTP) rate was 58% for p21-positive compared with 33% of p21-negative cases (p=0.036).
  • In conclusion, p21WAF1/CIP1 expression levels seem to be correlated with tumor status at the time of diagnosis and can predict TTP in a selected group of patients.
  • [MeSH-major] Cyclins / biosynthesis. Cystadenocarcinoma, Serous / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / secondary. Carcinoma, Endometrioid / surgery. Cell Cycle. Cisplatin / administration & dosage. Cyclin-Dependent Kinase Inhibitor p21. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / genetics. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / secondary. Cystadenocarcinoma, Mucinous / surgery. Disease Progression. Female. Genes, p53. Humans. Life Tables. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasm, Residual. Omentum. Ovary / metabolism. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11078810.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Neoplasm Proteins; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Jeremic K, Gojnic M, Milenković V, Petković S, Stojnić J, Lazović G, Berisavac M, Jeremić J: Treatment for infertility and risk of invasive epithelial ovarian cancer--a case report. Clin Exp Obstet Gynecol; 2006;33(3):190-1
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for infertility and risk of invasive epithelial ovarian cancer--a case report.
  • Her history revealed salpingo-oophorectomy for mucinous cystadenofibroma of the left ovary eight years before and cystectomy of the right ovary three years before.
  • After the antibiotic treatment, laparatomy was performed and a multilocular right adnexal tumor was found.
  • The right salpingo-oophorectomy was performed and pathological diagnosis was mucinous ovarian adenocarcinoma.
  • Two weeks later, radical surgery was carried out and chemotherapy was applied.
  • There is an urgent need for clear interpretation of the link between ovarian stimulation and ovarian cancer.
  • An association between ovarian stimulation treatment and ovarian cancer has still not been completely proven.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Gonadotropins / adverse effects. Humans. Infertility, Female / therapy. Neoplasm Invasiveness. Ovariectomy. Ovulation Induction / adverse effects

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • Genetic Alliance. consumer health - infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089588.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Gonadotropins
  •  go-up   go-down


27. Tang L, Zheng M, Xiong Y, Ding H, Liu FY: [Clinical characteristics and prognosis of epithelial ovarian cancer in young women]. Ai Zheng; 2008 Sep;27(9):951-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
  • BACKGROUND & OBJECTIVE: Epithelial ovarian cancer mostly appears in aged women, but rarely in young women.
  • Little is known about the clinical characteristics and prognosis of epithelial ovarian cancer in women aged below 35 years.
  • This study was to evaluate the clinical characteristics, treatment, survival and prognosis of young patients with epithelial ovarian cancer.
  • METHODS: A total of 71 patients with confirmed epithelial ovarian cancer under the age of 35 years between Jun.1980 and Dec.
  • The average maximum diameter of the tumor was 13.7 cm.
  • The tumor was located at one side of the ovary in 52 cases (73.2%).
  • Serous adenocarcinoma (40 cases, 56.3%) and mucinous adenocarcinoma (22 cases, 30.9%) were the most common pathologic types.
  • There were 42 cases (59.2%) of well-differentiated tumor, 18 cases (25.4%) of moderately-differentiated tumor and 11 cases (15.5%) of poorly differentiated tumor.
  • Sixty-eight patients received platinum and paclitaxel-based chemotherapy before or after operation.
  • Twelve patients achieved tumor free survival (80.0%) out of 15 patients (Ia, G1) underwent conservative surgery.
  • Pathological grade and residual tumor size were independent prognostic factors affecting ovarian cancer.
  • CONCLUSIONS: Young women with epithelial ovarian cancer under the age of 35 years mostly have serous adenocarcinoma; tumors are normally unilateral; and the prognosis is good.
  • The ovarian function can be preserved in part of stage Ia and Grade I patients.
  • Pathological grade and residual tumor size are independent prognostic factors of epithelial ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / surgery. Cystadenocarcinoma, Serous / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Female. Follow-Up Studies. Humans. Hysterectomy. Lymph Node Excision. Neoplasm Staging. Neoplasm, Residual / pathology. Ovariectomy. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Taxoids / therapeutic use. Tumor Burden. Young Adult


28. Angelescu N, Bordea A, Popa E, Constantinescu N, Zodieru I, Mircea N: [Pseudomyxoma peritonei (gelatinous peritonitis )]. Chirurgia (Bucur); 2001 Sep-Oct;96(5):443-51
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pseudomyxoma peritonei (P.P.) is characterised by the presence in the peritoneal cavity of 3 elements--mucinous neoplasic cells, mucinous ascites and diffuses mucinous implants.
  • The patients were submitted to variate surgical procedures, based on the benign (4 cases) or malignant (2 cases) character of the disease and on the origin of the lesions: cystadenoma of the appendix with secondary tumours of the ovary (the 2 females) and, respectively, cystadenoma and cytsadenocarcinoma of the appendix, mucinous paraenteric cyst with pseudomyxoma retroperitonei, mucinous recto-sigmoidian neoplasm (the 4 men).
  • We practiced intraperitoneal chemotherapy with Thio-Tepa in 5 cases (intraoperative in 4 cases) and systemic, with 5-FU and mytomicine, in one case.
  • The origin of the disease is the appendix (70-80%) and less frequently the ovary.
  • It was divided in two distinct forms: disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
  • The treatment associates radical surgery and intraperitoneal chemohyperthermia, in specialised centres, but the prognosis still remains poor (50-70% 5-year global survival rate).
  • [MeSH-major] Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12731187.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 26
  •  go-up   go-down


29. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
  • Nonsmall cell neuroendocrine carcinoma (NSCNEC) of the ovary is a rare and aggressive tumor commonly associated with other surface epithelial and germ cell neoplasms.
  • In 8 cases, NSCNEC was associated with other epithelial neoplasms, including mucinous neoplasms of low malignant potential, mucinous carcinoma, endometrioid carcinoma, mixed endometrioid and mucinous carcinoma, and a high-grade carcinoma, not otherwise specified.
  • In 2 cases, the tumor was associated with a mature cystic teratoma; one of them also containing an invasive moderately differentiated adenocarcinoma.
  • A single case was associated with a benign ovarian cyst.
  • The latter case had a dermoid cyst in the contralateral ovary.
  • NSCNEC represented anywhere from 10% to 90% of the ovarian tumor.
  • Seven patients were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by chemotherapy.
  • One patient had a bilateral salpingo-oophorectomy with omentectomy and appendectomy followed by chemotherapy; 1 patient had a total abdominal hysterectomy with right salpingo-oophorectomy followed by chemotherapy; one had a bilateral salpingo-oophorectomy followed by chemotherapy, and one had a right salpingo-oophorectomy with appendectomy followed by chemotherapy.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Neuroendocrine / pathology. Immunoenzyme Techniques. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


30. Iervolino P, Palmieri M, Rotondi M, D'Alessandro P, Iuliano R: [Borderline ovarian tumors. Retrospective analysis of 20 cases]. Minerva Ginecol; 2001 Feb;53(1 Suppl 1):97-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Borderline ovarian tumors. Retrospective analysis of 20 cases].
  • BACKGROUND: To evaluate the clinical features, the surgical management and outcome of 20 patients with stage-I borderline ovarian tumors.
  • METHODS: Twenty cases of FIGO stage-I ovarian tumors, aged from 31 to 58 years (mean 37 years) have been reviewed.
  • Minimal requirements for conservative management were adequate staging and complete information about the therapeutic options.
  • Factors important in the choice of the treatment were, age, wish to preserve fertility, histologic type and grade, and the stage of the tumour.
  • Thirteen (65%) were with mucinous cystadenoma of borderline malignancy, 7 cases (35%) were of serous type.
  • One patient underwent enucleation of ovarian tumor and biopsy of contralateral ovary.
  • Any patient were treated with chemotherapy after operation.
  • CONCLUSIONS: Conservative surgery remains a therapeutic option in selected patients with borderline ovarian tumors.
  • Prolonged intensive follow-up is required for women treated conservatively for borderline malignant ovarian tumours.
  • [MeSH-major] Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11526732.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


31. Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, Masucci GV: Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol; 2006 Oct;103(1):145-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer.
  • OBJECTIVES: Major histocompatibility complex antigens are mandatory for the immune response, and a genetic imbalance may be linked to tumor escape.
  • We have previously characterized a cluster of ovarian cancer patients with high incidence of HLA-A2.
  • METHODS: A population-based set of 97 patients with confirmed epithelial ovarian cancer were recorded in a database by age, histology, stage, surgery and treatment.
  • At the time the study was initiated, the majority of the patients were not alive and HLA-A2 expression was therefore determined by PCR/sequence-specific oligonucleotide hybridization using DNA extracted from paraffin-imbedded tissue specimens.
  • 44% were serous adenocarcinomas, 28% endometrioid, 6% mucinous, 13% clear cell carcinomas, 7% undifferentiated and 2% other epithelial tumors.
  • CONCLUSIONS: HLA-A2 is a negative factor for survival in women with serous adenocarcinomas of the ovary in stages III-IV.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. HLA-A2 Antigen / biosynthesis. Ovarian Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / immunology. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / immunology. Cystadenocarcinoma, Serous / pathology. Female. Humans. Middle Aged. Neoplasm Staging. Paraffin Embedding. Polymerase Chain Reaction. Prognosis. Proportional Hazards Models. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16542716.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA-A2 Antigen
  •  go-up   go-down


32. Li M, Pan LY, Huang HF, Lang JH: [Epithelial ovarian tumors in adolescence: a study of clinical features and treatment]. Zhonghua Fu Chan Ke Za Zhi; 2004 Sep;39(9):598-601
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelial ovarian tumors in adolescence: a study of clinical features and treatment].
  • OBJECTIVE: To study the clinical feature, diagnosis and treatment of epithelial ovarian tumors in adolescent patients.
  • METHODS: A retrospective analysis was performed on 29 patients of epithelial ovarian tumors between the age of 13 and 19 during the period of 1983 - 2002 in Peking Union Medical College Hospital.
  • The histological types included mucinous tumor in twenty-two cases, serous tumor in six, and endometroid tumor in one case.
  • Of benign tumor group, an abdominal unilateral salpingo-oophorectomy was performed on nine cases.
  • A cisplatin combined chemotherapy was given to four patients with malignant tumors.
  • CONCLUSIONS: The incidence of epithelial ovarian tumors during adolescence increases with age.
  • Mucinous tumor is the most common histological type in adolescent patients.
  • The therapeutic strategy should be individualized, and surgical approach should consider both cure and preservation of fertility in malignant cases.
  • [MeSH-major] Carcinoma / therapy. Ovarian Neoplasms / therapy. Puberty
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Laparoscopy. Neoplasm Staging. Ovary / surgery. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15498186.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, Modesitt SC, Lu KH, Geisler JP, Higgins RV, Magtibay PM, Cohn DE, Powell MA, Chu C, Stehman FB, van Nagell J: Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol; 2002 Oct;87(1):1-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy.
  • OBJECTIVES: The purpose of this study was to determine the recurrence rate, survival, and pregnancy outcome in patients with Stage IA and Stage IC invasive epithelial ovarian cancer treated with unilateral adnexectomy.
  • METHODS: A multi-institutional retrospective investigation was undertaken to identify patients with Stage IA and IC epithelial ovarian cancer who were treated with fertility-sparing surgery.
  • All patients with ovarian tumors of borderline malignancy were excluded.
  • Long-term follow-up was obtained through tumor registries and telephone interviews.
  • The time and sites of tumor recurrence, patient survival, and pregnancy outcomes were recorded for every patient.
  • RESULTS: Fifty two patients with Stage I epithelial ovarian cancer treated from 1965 to 2000 at 8 participating institutions were identified.
  • Cell type was distributed as follows: mucinous, 25; serous, 10; endometrioid, 10; clear cell, 5; and mixed, 2.
  • Twenty patients received adjuvant chemotherapy (mean 6 courses, range 3-12 courses).
  • Five patients developed tumor recurrence 8-78 months after initial surgery.
  • Sites of recurrence were as follows: contralateral ovary, 3; peritoneum, 1; and lung, 1.
  • At present, 50 patients are alive without evidence of disease and 2 have died of disease 13 and 97 months after initial treatment.
  • CONCLUSION: The long-term survival of patients with Stage IA and IC epithelial ovarian cancer treated with unilateral adnexectomy is excellent.
  • Fertility-sparing surgery should be considered as a treatment option in women with Stage I epithelial ovarian cancer who desire further childbearing.
  • [MeSH-major] Fertility. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Epithelial Cells / pathology. Female. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Ovariectomy / methods. Pregnancy. Pregnancy Complications, Neoplastic. Pregnancy Outcome. Retrospective Studies. Survival Rate. Treatment Outcome






Advertisement